KR20110047745A - A composition comprising the Ulmus davidiana var. japonica extract there of having anti-asthmatic effect - Google Patents

Abstract

PURPOSE: A pharmaceutical composition containing Ulmus davidiana var. japonica extract with antasthmatic activity is provided to health food or health supplementary food. CONSTITUTION: A pharmaceutical composition for preventing or treating asthma contains Ulmus davidiana var. japonica extract as an active ingredient, isolated by water, alcohol, or mixture thereof. The alcohol is ethanol or methanol. A health food for preventing or treating asthma contains Ulmus davidiana var. japonica extract as an active ingredient.

Description

Pharmaceutical composition containing the extract of Root-root skin having anti-asthmatic activity {A composition comprising the Ulmus davidiana var. japonica extract there of having anti-asthmatic effect}

The present invention relates to pharmaceutical compositions having anti-asthmatic activity.

Asthma is a disease characterized by airway hypersensitivity to various stimuli. Clinical symptoms such as wheezing, dyspnea, and cough caused by extensive airway narrowing are often healed naturally or reversibly by treatment. Can improve. Asthma can be divided into exogenous and endogenous asthma depending on the cause. In exogenous asthma, it is asthma that causes symptoms when exposed to the causative antigen. A skin test or bronchial challenge test for the causative antigen is positive and usually occurs young. Recently, house dust mites are the most common cause antigen, and pollen, animal epithelium, mold, etc. act as the cause antigen.

Until now known asthma treatment has been used steroids such as glucocorticoid (glucocorticoid). However, the steroid is powerful in terms of effectiveness, but there is a big problem of drug side effects. Therefore, the development of a therapeutic agent with excellent effects and fewer side effects is urgently required. For this purpose, the development of therapeutic agents using natural substances extracted from plants is in progress.

The present inventors have made many efforts, yugeunpi (root bark Elm) (Ulmus want to explore the plant material which can be used in the treatment of asthma davidiana var. The present invention was completed by confirming the efficacy of the root canal as a therapeutic agent for asthma by having bronchial mucus secretion and inflammatory cell infiltration inhibitory activity in the bronchial tissue in an ovalbumin-sensitized asthma model.

An object of the present invention is the root of the roots (Elm root bark) ( Ulmus davidiana var. japonica ) to provide a composition for preventing or treating asthma containing the extract as an active ingredient and a method for preventing or treating the same.

Another object of the present invention to provide a health food for the prevention or improvement of asthma containing the root extract as an active ingredient.

In order to achieve the above object, the present invention is extracted with water, alcohol or a mixture of the roots of the root (Elm root bark) ( Ulmus davidiana var. japonica ) provides a pharmaceutical composition for the prevention or treatment of asthma containing the extract as an active ingredient.

In another aspect, the present invention provides a health food for preventing or improving asthma containing the extract of the roots of the root of the roots extracted with water, alcohol or a mixture thereof as an active ingredient.

In addition, the present invention provides a method for preventing or treating asthma in the subject, comprising administering to the subject a pharmaceutically effective amount of the extract of the myodermis.

Root skin of the present invention (elm root bark) ( Ulmus davidiana var. japonica ) extract can be used as a pharmaceutical composition or dietary supplement or dietary supplement for the prevention and treatment of asthma.

Hereinafter, the term used by this invention is demonstrated.

As used herein, the term "prevention" means any action that inhibits asthma by administration of a composition of the present invention.

As used herein, the terms "treatment" and "improvement" refer to any action in which asthma is improved or beneficially altered by administration of a composition of the present invention.

As used herein, the term "administration" means providing a subject with a composition of the present invention in any suitable manner.

As used herein, the term "individual" means any animal, including humans, monkeys, dogs, goats, pigs, or mice, having asthma by administering the composition of the present invention.

As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit or risk ratio applicable to medical treatment, which means the type of disease, the severity, the activity of the drug, the drug Sensitivity to, time of administration, route of administration and rate of administration, duration of treatment, factors including drug used concurrently, and other factors well known in the medical arts.

Hereinafter, the present invention will be described in detail.

The present invention is the root of the roots (elm root bark) extracted with water, alcohol or a mixture thereof ( Ulmus davidiana var. japonica ) provides a pharmaceutical composition for the prevention or treatment of asthma containing the extract as an active ingredient.

Root skin is used for young leaves and bark for edible use, stems, roots and bark for medicinal use, and fruit is used as an insect repellent. Root skin is a health ingredient that has been used for a long time as a herbal medicine and edible extract of the present invention extracted therefrom also has no problems such as toxicity and side effects. It has been used to control the metabolism of water, act on the stomach, to reduce swelling, to cool the urine, to swell the body, or to have skin diseases. However, none of these studies studied the anti-asthma effect of root bark.

The roots may be used without limitation, such as those grown or commercially available. In addition, the root extract of the root of the present invention can be prepared as follows. The root skin is washed with water and then dried for 7 days at shade and room temperature. After crushing the dried root skin, it is put in an extraction container, and extracted with a solvent for a predetermined time at an appropriate temperature. After obtaining the extract of the roots, the solids may be removed using a filter paper or the like, the suspension may be centrifuged, and the supernatant may be filtered under reduced pressure. The extraction solvent is preferably a solvent selected from water, an alcohol or a mixture thereof, preferably a lower alcohol of C ₁ to C ₄ or a mixed solvent thereof, more preferably 70% ethanol, but is not limited thereto. It doesn't happen. The amount of the extraction solvent is 2 to 15 times the weight of dry root skin. The extraction method may be an extraction method such as hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction, it may be preferably extracted one to five times by the ultrasonic extraction method. The temperature at the time of extraction is preferably 10 ° C. to 100 ° C., more preferably room temperature. The extraction time is 30 minutes to 4 hours, preferably 1 hour.

In a specific embodiment of the present invention, the root of the root (Elm root bark) ( Ulmus ) davidiana var. japonica ) Extracts Inhibit the Production of Immunoglobulin E (IgE), Interleukin-4 (IL-4), and Interleukin-5 (IL-5) in Bronchoalveolar Lavage in Asthmatic Animal Models with Ovalbumin Sensitization , Activity inhibiting eosinophil increase, inhibiting bronchial inflammatory cell infiltration in waste tissue and restoring damage to epithelial cells (see Tables 1 to 3 and Figures 1 to 5). In addition, the bronchial remodeling process in asthma patients causes pulmonary deterioration over time, and the extract of the myofibril of the present invention inhibits the secretion of mucus that may be caused by the remodeling process (see FIG. 6). . The mechanism of asthma reactions is through a variety of reactions, including the various types of cells, regulators and mediators involved in characteristic inflammatory and tissue remodeling. Thus, the root extract of the present invention can be usefully used as a pharmaceutical composition for the prevention or treatment of asthma involved in the inflammatory response and tissue remodeling.

The pharmaceutical composition comprising the powder of the present invention or the extract thereof comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.

Pharmaceutical compositions comprising the powder of the present invention or extracts thereof may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

The pharmaceutical dosage forms of the myofibril extract of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.

Pharmaceutical compositions comprising extracts according to the invention are in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Examples of carriers, excipients and diluents that can be included in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the extract of the present invention is preferably administered at 0.0001 to 1 g / kg, preferably at 0.001 to 200 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

In addition, the pharmaceutical composition of the present invention may be administered orally or parenterally, and when parenteral administration is selected for external or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method. It is preferable to, but not limited to.

In another aspect, the present invention provides a health food for preventing or improving asthma containing the extract of the roots of the root of the roots extracted with water, alcohol or a mixture thereof as an active ingredient.

In a specific embodiment of the present invention, the root extract was confirmed the inflammatory response of bronchial alveolar lavage fluid and bronchial mucus secretion inhibitory activity in the bronchial tissue in the asthma model (see FIGS. 1 to 6). Thus, the root extract of the present invention can be usefully used as a health food for the prevention or improvement of asthma involved in the inflammatory response and tissue remodeling.

There is no particular limitation on the kind of food. Examples of foods to which the above-mentioned substances may be added include dairy products including drinks, meat, sausages, breads, biscuits, rice cakes, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, gums and ice cream, various soups, Beverages, alcoholic beverages, vitamin complexes, and the like, and include all healthy foods in the conventional sense.

The root extract of the present invention may be added to a food as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its use purpose (for prevention or improvement). In general, the amount of the extract in the health food can be added at 0.01 to 15% by weight of the total food weight, the health beverage composition can be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml. have. However, in the case of long-term intake for health and hygiene or health control purposes, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

Health functional food of the present invention includes the form of tablets, capsules, pills, liquids and the like. The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the extract of the present invention may contain fruit flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.

In addition, the present invention provides a method for the prevention or treatment of asthma in a subject comprising administering to the subject a pharmaceutically effective amount of the extract of the roots.

In a specific embodiment of the present invention, the root extract was confirmed the inflammatory response of bronchial alveolar lavage fluid and bronchial mucus secretion inhibitory activity in the bronchial tissue in the asthma model (see FIGS. 1 to 6). Thus, the root extract of the present invention can be usefully used for the prevention or treatment of asthma involved in the inflammatory response and tissue remodeling.

The subject is a vertebrate and preferably a mammal, more preferably an experimental animal such as a rat, rabbit, guinea pig, hamster, dog, cat, and most preferably an ape-like animal such as a chimpanzee or gorilla.

The method of administration may be administered orally or parenterally, intraperitoneal, rectal, subcutaneous, intravenous, intramuscular, intrauterine dural, intracerebroventricular or intrathoracic It can be administered by injection.

The pharmaceutically effective amount is 0.0001 to 1 g / kg, preferably 0.001 to 200 mg / kg, but is not limited thereto. Dosage may vary depending on the weight, age, sex, health status, diet, duration of administration, method of administration, elimination rate, severity of disease, and the like of a particular patient. The pharmaceutical composition of the present invention may be administered several times daily to once a week depending on the half-life. The dosage does not limit the scope of the invention in any aspect.

Hereinafter, the present invention will be described in detail by Examples, Experimental Examples and Formulation Examples.

However, the following Examples, Experimental Examples, and Formulation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Experimental Examples, and Formulation Examples.

< Example  1> Root skin  Preparation of Extract

[Yu root skin (elm root bark) ( Ulmus davidiana var. japonica ) was purchased from HMAX (Jecheon, South Korea) and crushed after appraisal from Professor Dongguk University. 200 g or 20 g of the root skin prepared by the above method was immersed in 2 liters of 70% aqueous ethanol solution (70% EtOH) or water, stirred well, and then ultrasonically extracted at room temperature for 1 hour and filtered through a filter paper. After repeating the above procedure three times, the extract was concentrated under reduced pressure using a concentrator at 45 to 50 ℃, and then lyophilized to obtain a root extract.

As a result, a solvent extract of 1 g of water (5% yield) or 13.09 g of 70% ethanol (6.5% yield) could be prepared.

< Experimental Example  1> Bronchoalveolar lavage fluid  Eosinophil Analysis

<1-1> Airway of Experimental Animal Sensitization  Antigen administration

Female (Balb / c) (approximately 20 g) of 8-week-old specific pathogen uninfected rats (20 g) was purchased from Daehan Biolink Co., Ltd., and 20 ㎍ of 2 mg aluminum hydroxide (Sigma A8222) and egg white albumin (Sigma A5503). 100 μl of the suspended phosphate buffer solution (pH 7.4) was sensitized by intraperitoneal injection twice at two week intervals. 21, 22, and 23 days after the start of the experiment, a phosphate buffer solution containing 1% egg white albumin was sprayed into an airtight container containing mice for 30 minutes using an ultrasonic nebulizer, and the negative control group did not cause airway sensitization. (A: 5 animals), PBS 50 mg / kg administration group (B: 8 mice) as a control group, montelukast treatment group (C: 7 mice) as a positive control group, Example 1 as an experimental group The myofibril extract obtained in -1 was suspended in phosphate buffer solution, and then experimented with the group (D and E: 8 mice) orally administered 100 or 200 mg / kg 1 hour before challenge. Twenty-four hours after the last challenge, an excess of pentobarbital (Sigma P3761) was administered and lethal before bronchial incision was performed. Bronchoalveolar lavage fluid (BALF) was obtained by inhalation of 0.6 ml three times by cannula insertion into the trachea.

<1-2> With egg white albumin Sensitized  In animal models Of bronchoalveolar lavage  Eosinophil Analysis

100 μl of the bronchial alveolar solution of each experimental group obtained in Experimental Example 1-1 was placed on a slide and centrifuged using a cytospin instrument (Hanil, Korea) to fix cells on the slide. Total cell number except dead cells stained with Trypan blue was calculated using a hemocytometer and repeated three times (Daigle I & Simon HU. Swiss Med. Wkly., 131: 231-237 , 2001). Eosinophil counts were determined after staining with Diff-Quick reagent (Sysmex, Cat No. 38721, Switzerland) and calculated in the same manner as total cell numbers. Statistical analysis was performed by Student's t-test, and significance was expressed by p value.

As a result, as shown in Table 1 and FIG. 1, the total inflammatory cell number of the bronchoalveolar pulmonary fluid when the airway was not sensitized as a negative control was 2.3 ± 0.9 × 10 ⁴ cells / ml, among which eosinophils ) Was 0%, and the total number of inflammatory cells was 4491.1 ± 820 × 10 ⁴ cells / mouse in sensitized with egg albumin as a positive control and challenged with PBS. Occupied. However, the total inflammatory cell number when treated with the extract of the root of the present invention In the case of 100 mg / kg administration, the dose of 3642.4 ± 916 × 10 ⁴ cells / mouse and 200 mg / kg were decreased by 38% to 2800.0 ± 847 × 10 ⁴ cells / mouse, and the eosinophil count was 200 mg / kg. In the case of administration, a decrease of more than 40% was observed.

Kinds Per mouse
Total inflammatory cell count (only) Per mouse
Eosinophil count (only) Normal mouse 2 or less Not observed Egg albumin sensitization-phosphate buffer treatment 4491 ± 820 1942 ± 296 UD-1; Egg albumin sensitization-Yugi skin (100 /) extract treatment 3642 ± 916  1676 ± 397 UD-2; Egg albumin sensitization-Yugeunpi (200 /) extract treatment 2800 ± 847 1000 ± 387 Egg albumin sensitization-montelukast treatment   980 ± 423   340 ± 91

< Experimental Example  2> immunoglobulin E ( IgE ) analysis

Immunoglobulin E (IgE) The assay used a sandwich-type enzyme-linked immunosorbent assay (ELISA) method. Specifically, 100 μl of the bronchial alveolar fluid of each experimental group obtained in Experimental Example 1-1 was placed in a 96-well plate to which capturing IgE antibody was attached to induce an antigen-antibody reaction at room temperature for 1 hour. At this time, the plate attached with immunoglobulin E was blocked for 1 hour using 5% skim milk powder in advance and washed three times with a washing solution (PBS + 0.1% tween 20). After the antigen-antibody reaction was finished, three washings were performed, followed by 100 μl of a detection IgE antibody (mouse, PharMingen, San Diego, USA) bound with horseradish peroxidase (HRP). Was added to the wells and allowed to react for 1 hour. After the reaction, the solution was washed five times with ortho phenylene diamine (OPD) and hydrogen peroxide (H ₂ O ₂ ) as a substrate to induce a color reaction, and then measured the absorbance at 405 ㎚ The amount of immunoglobulin E in bronchial alveolar fluid was measured.

As a result, in the mice sensitized with egg albumin, as shown in Table 2 and Figure 2, it was confirmed that the content of immunoglobulin E increased rapidly in the rats treated with only phosphate buffer solution, and the phosphate buffer in the treatment group of the myofibril extract. Compared with the solution treatment, the production of immunoglobulin E was significantly reduced by 30% when 100 mg / kg dose of myocardium extract was administered and by 40% when 200 mg / kg.

Kinds Immunoglobulin E Content (ng / mL) Immunoglobulin E production inhibition rate (%) Normal rat  1.0 or less Egg albumin sensitization-phosphate buffer treatment 19.6 ± 4.0 0 UD-1; Egg albumin sensitization-Yugi skin (100 mg / kg) extract treatment 12.59 ± 2.9 37.0 UD-2; Egg albumin sensitization-Yugi skin (200 mg / kg) extract treatment 11.78 ± 1.1 40 Egg albumin sensitization-montelukast treatment 11.55 ± 3.9 42

< Experimental Example  3> cytokine ( IL -4, IL -5) analysis

Specific reaction to the cytokines to measure the cytokine (cytokine) interleukin-4 (IL-4) and interleukin-5 (IL-5) content of the bronchial alveolar fluid of each experimental section obtained in Experimental Example 1-1 ELISA kit (Biosource, USA) was used, and the content of each cytokine was measured according to the manufacturer's method.

As a result, it was observed that the production of bronchial alveolar interleukin-4 and interleukin-5 was significantly increased in rats sensitized with egg albumin as shown in Table 3 and FIGS. 3 and 4, and 100 mg / kg, 200 As a result of measuring the contents of interleukin-4 and interleukin-5 in both mg and kg doses of dermal extract, IL-4 showed 20% (100 mg / kg), 50% (200 mg / kg), and IL-5 It was confirmed that there was a significant inhibitory effect of about 56% (100 mg / kg) and 61% (200 mg / kg).

Kinds IL-4 (pg / ml) IL-5 (pg / ml) Normal rat 55 or less 75 or less Egg albumin sensitization-phosphate buffer treatment 118.2 ± 35.0 184.9 ± 62.1 UD-1; Egg albumin sensitization-Yugi skin (100 mg / kg) extract treatment 95.4 ± 31.3 81.3 ± 33.5 UD-2; Egg albumin sensitization-Yugi skin (200 mg / kg) extract treatment 59.7 ± 20.2 71.0 ± 46.6 Egg albumin sensitization-montelukast treatment  76.2 ± 42.0  62.2 ± 7.6

< Experimental Example  4> Using histopathological method Anti-asthma  Identify the effect

For histopathological experiments, rat lung tissue was fixed with 10% neutral buffer-formalin for 24 hours and paraffin embedding was performed. Embedding tissue was cut into 4 mm thick sections to make sections, stained with hematoxylin and Eosin Y (ThermoShandon, USA) and then encapsulated with Dakocytomation (Dakocytomation, Denmark). The stained and sealed slides were examined under an optical microscope.

As a result, as shown in Figure 5 induces asthma with egg white albumin and the control group (B) administered only phosphate buffer solution can be seen that many inflammatory cells, including eosinophils are infiltrated around the bronchioles and epithelial cells are damaged On the other hand, in the experimental group to which the myofibril extract was administered, inflammatory cells, including eosinophils, were markedly decreased and epithelial cell damage was hardly seen (D and E).

< Experimental Example  5> bronchial mucus inhibitory effect

When bronchial remodeling occurs, the sticky mucus secretion is excessive. To determine whether the goblet cells, which are mucus-secreting cells, have been excessively proliferated, the lung tissue sections of Experimental Example 4 were replaced with Periodic acid-Schiff (PAS). , IMEB INC).

As a result, as shown in Figure 6, hyperplasia of goblet cells occurs in bronchus (B) of egg white albumin-induced rats, whereas hyperplasia did not appear in the experimental group administered with the myofibril extract (D and E).

Hereinafter, an example of the preparation of the pharmaceutical composition comprising the root-derived powder of the present invention or the extract thereof will be described, but the present invention is not intended to be limited thereto but merely to be described in detail.

< Formulation example  1> Powder  Produce

Root Skin Extract 500 mg

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

< Formulation example  2> Preparation of Tablet

Root Skin Extract 500 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

< Formulation example  3> Preparation of capsule

Root Skin Extract 500 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

< Formulation example  4> Preparation of Injection

Root Skin Extract 500 mg

Appropriate sterile distilled water for injection

pH adjuster

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

< Formulation example  5> Liquid  Produce

100 mg of root extract

10 g of isomerized sugar

5 g of mannitol

Purified water

After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution is prepared by sterilization.

< Formulation example  6> Manufacture of health food

Root skin extract 1000 mg

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

0.13 mg of vitamin

0.15 mg of vitamin B ₂

0.5 mg of vitamin B ₆

Vitamin B ₁₂ 0.2 g

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

Folate 50 ㎍

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

< Formulation example  7> Manufacture of health drinks

Root skin powder 1000 mg

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated and then stored in the present invention For the preparation of healthy beverage compositions.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Figure 1 shows the roots of total inflammatory cells and eosinophils in bronchoalveolar lavage fluid after sensitization of airway ( Ulmus davidiana var. japonica ) shows the effect of the extract.

Figure 2 is a measure of the content of immunoglobulin E in the alveolar lavage fluid.

3 is a diagram measuring the content of interleukin 4 in the alveolar lavage fluid.

Figure 4 is a diagram measuring the content of interleukin 5 in the alveolar lavage fluid.

Figure 5 is a diagram showing the histochemical results of the tissues of the bronchoalveolar sensitization after airway sensitization, (A) when airway sensitization, (B) airway sensitization with egg white albumin, (C) montelukast treatment In the case of (D) 100 mg / kg of the root extract, the figure shows the effect on the bronchial tissue when 200 mg / kg of the root extract.

6 is a diagram showing the bronchial sensitization after PAS staining, (A) when airway sensitization, (B) airway sensitization with egg white albumin, (C) montelukast treatment (D) A diagram showing the effects on the bronchial tissues when 100 mg / kg of the root extract was treated. (E) 200 mg / kg of the root extract.

Claims (9)

A pharmaceutical composition for the prevention or treatment of asthma, containing as an active ingredient extract of Ulmus davidiana var. Japonica extracted with water, alcohol or a mixture thereof. The pharmaceutical composition of claim 1, wherein the alcohol is a C ₁ to C ₄ lower alcohol. The pharmaceutical composition according to claim 2, which is ethanol or methanol. Health food for the prevention or improvement of asthma containing the extract of the roots of the roots extracted with water, alcohol or a mixture thereof as an active ingredient. The health food according to claim 4, wherein the alcohol is a C ₁ to C ₄ lower alcohol. The health food according to claim 5, which is ethanol or methanol. A method of preventing or treating asthma in a subject, comprising administering to the subject a pharmaceutically effective amount of the extract of the roots. 8. The method of claim 7, wherein the alcohol is a C ₁ to C ₄ lower alcohol. The method of claim 8, wherein the process is ethanol or methanol.

Images